Veracyte is trading 4.46% down at $42.66, with no confirmed company-specific announcement identified to explain the October 7, 2026 decline.
- Broader risk-off pressure from Treasury yields and oil concerns is weighing on equities; XBI was reported down about 3.4%.
- Latest coverage focuses on Decipher prostate-test data presented at ASTRO, but does not establish that it caused the drop.